Detalles de la búsqueda
1.
Deep Learning-based Propensity Scores for Confounding Control in Comparative Effectiveness Research: A Large-scale, Real-world Data Study.
Epidemiology
; 32(3): 378-388, 2021 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33591049
2.
Addressing current challenges and future directions in immuno-oncology: expert perspectives from the 2017 NIBIT Foundation Think Tank, Siena, Italy.
Cancer Immunol Immunother
; 68(1): 1-9, 2019 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-30564889
3.
CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study.
Lancet Oncol
; 16(8): 949-56, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-26179200
4.
Facts and Hopes on Biomarkers for Successful Early Clinical Immunotherapy Trials: Innovative Patient Enrichment Strategies.
Clin Cancer Res
; 30(8): 1448-1456, 2024 Apr 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38100047
5.
Correlation Between Early Trends of a Prognostic Biomarker and Overall Survival in Non-Small-Cell Lung Cancer Clinical Trials.
JCO Clin Cancer Inform
; 7: e2300062, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37922432
6.
Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor.
Clin Cancer Res
; 28(4): 770-780, 2022 02 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34782366
7.
Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade.
J Immunother Cancer
; 10(5)2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35577503
8.
Dendritic cell-based vaccination of patients with advanced pancreatic carcinoma: results of a pilot study.
Cancer Immunol Immunother
; 60(8): 1097-107, 2011 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-21547597
9.
Combination immunotherapy and active-specific tumor cell vaccination augments anti-cancer immunity in a mouse model of gastric cancer.
J Transl Med
; 9: 140, 2011 Aug 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-21859450
10.
Immunotherapy of peritoneal carcinomatosis with the antibody catumaxomab in colon, gastric, or pancreatic cancer: an open-label, multicenter, phase I/II trial.
Onkologie
; 34(3): 101-8, 2011.
Artículo
en Inglés
| MEDLINE | ID: mdl-21358214
11.
Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma.
Blood Adv
; 5(22): 4762-4770, 2021 11 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-34581757
12.
Immunotherapy of cancer: key findings and commentary on the third Tegernsee conference.
Oncologist
; 15(1): 112-8, 2010.
Artículo
en Inglés
| MEDLINE | ID: mdl-20061401
13.
Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies.
Cancer Cell Int
; 10: 44, 2010 Nov 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-21044305
14.
High-grade, chemotherapy-resistant ovarian carcinomas overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody.
Am J Obstet Gynecol
; 203(6): 582.e1-7, 2010 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-20870202
15.
Primary cervical carcinoma cell lines overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody.
Int J Gynecol Cancer
; 20(9): 1440-7, 2010 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-21370592
16.
Phase II study of the human anti-epithelial cell adhesion molecule antibody adecatumumab in prostate cancer patients with increasing serum levels of prostate-specific antigen after radical prostatectomy.
Urol Int
; 85(4): 386-95, 2010.
Artículo
en Inglés
| MEDLINE | ID: mdl-20606402
17.
PK/PD Mediated Dose Optimization of Emactuzumab, a CSF1R Inhibitor, in Patients With Advanced Solid Tumors and Diffuse-Type Tenosynovial Giant Cell Tumor.
Clin Pharmacol Ther
; 108(3): 616-624, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32575160
18.
Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients.
J Immunother Cancer
; 8(2)2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-33097612
19.
Long-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumour.
Eur J Cancer
; 141: 162-170, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33161240
20.
The PET-Tracer 89Zr-Df-IAB22M2C Enables Monitoring of Intratumoral CD8 T-cell Infiltrates in Tumor-Bearing Humanized Mice after T-cell Bispecific Antibody Treatment.
Cancer Res
; 80(13): 2903-2913, 2020 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32409308